lower ew pt stiffen
weve adjust ew sale estimate report
vs prior report in-lin high end
incl royalti mitral/tricuspid in-lin w/ high end
guidanc rang cc model ep
within mgmt guidanc lower dcf pt
basi increas tavr competit maintain buy
thought tavr envis ew show increas us tavr
momentum aid cap program centera
us like cannib corevalv frame refer
increment quarterli unit equat ex-u read ew
commentari close suspect remain suffici geographi
europ arent overli price sensit support self-expand share
gain centera allow least firm balloon expand
ultra
think next year believ favor low risk trial result
perhap equival mortal lower morbid
stroke new onset atrial fibril serv least maintain ww
market momentum despit bigger base aggress price ex-
us suspect addit reinforc overal tavr messag
help bolster/sustain pace recruit elderli patient arent
surgic queue low risk also hasten cannib surgeri
amongst patient yoa dont requir cabg aneurysm repair and/
multipl valv replacement/repair procedur us instanc
previous estim annual surgeri age cohort could
readili convert link tavr anticip us unit market
growth rate instanc versu around product revenu growth
year base unit could ration assum
growth ascrib recruit non-surg elderli
addit surgic convers total unit ew cours
princip beneficiari continu market strength
lotu price relat competit pressur europ seen
weve modestli strengthen share assumpt slightli
worsen market asp assumpt continu pg
tr target
mid-term competit off-set us cours introduct centera self-
expand segment latter part given heighten competit environ weve
modestli downwardli adjust long term ew tavr busi assumpt similarli upwardli
adjust dcf discount rate slightli
thesi invest thesi ew remain unchang princip driven share posit
tavr market exceed link similar size mitral/tricuspid
opportun circa continu market momentum help allay concern held
regard size underli preval pool also feel cours
investor attent becom reliabl focus mitral/tricuspid adjac
preval us mitral/tricuspid patient versu aortic stenosi patient link
valuat risk price target sum assign base busi
inclus tavr associ mitral/tricuspid adjac base busi dcf
assum ew tavr overal sale ex-mitral/tricuspid
unburden invest structur heart adjac presum oper margin
base busi thusli defin employ discount rate termin growth rate
presum develop non-thvt growth driver mitral tricuspid consid
termin valu contribut combin segment assum market
ew hold share associ oper margin point time discount
rate termin growth rate given larger patient size mitral/tricuspid adjac
interven trans-cathet learn tavr off-set increas technical/clin
uncertainti dont feel market assumpt year henc unreason
like take tavr year achiev sale trans-cathet mitral sale alreadi total
dont assign valu mitral/tricuspid posit cash flow prior
consider drag invest period princip risk thesi includ
over-estim address aortic mitral tricuspid preval pool technical/clin
uncertainti mitral/tricuspid heighten competit thvt higher expect thvt
page
page
page
million except per share surgeri expens inc interest incom adjust analysisgross sg analysistot sale sale cc cc ex cc incl cc incl cardioband vasc forma corpor
edward lifesci corp focus technolog treat structur heart diseas
critic ill patient design develop manufactur market product treat cardiovascular
diseas product technolog categor three area surgic heart valv therapi
transcathet heart valv critic surgic heart valv therapi portfolio includ
tissu heart valv heart valv repair product surgic replac repair patient
heart valv transcathet heart valv portfolio includ technolog design treat heart
valv diseas use catheter-bas approach oppos open surgic techniqu critic
portfolio product includ pulmonari arteri cathet dispos pressur transduc
advanc monitor system found mile lowel edward
headquart irvin ca
invest thesi ew remain unchang princip driven share posit tavr
market exceed link similar size mitral/tricuspid opportun circa
continu market momentum help allay concern held regard
size underli preval pool also feel cours investor
attent becom reliabl focus mitral/tricuspid adjac preval us
mitral/tricuspid patient versu aortic stenosi patient link
valuat risk
price target sum assign base busi inclus tavr
associ mitral/tricuspid adjac base busi dcf assum
ew tavr overal sale ex-mitral/tricuspid unburden invest
structur heart adjac presum oper margin base busi
thusli defin employ discount rate termin growth rate presum
develop non-thvt growth driver mitral tricuspid consid termin valu
contribut combin segment assum market ew hold
share associ oper margin point time discount rate
termin growth rate given larger patient size mitral/tricuspid adjac interven
trans-cathet learn tavr off-set increas technical/clin uncertainti
dont feel market assumpt year henc unreason like take tavr
year achiev sale trans-cathet mitral sale alreadi total
dont assign valu mitral/tricuspid posit cash flow prior consider
drag invest period
princip risk thesi includ over-estim address aortic mitral
tricuspid preval pool technical/clin uncertainti mitral/tricuspid heighten competit
thvt higher expect thvt price pressur
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
